Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEH200486 in Healthy Volunteers
NCT05569278Phase 1Completed
- Sponsor
- GE HealthCare
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mangaciclanol (4 arms), sponsored by GE HealthCare. Primary endpoints: Occurrence of IMP-related SAEs, TEAEs, and AEs, Injection site monitoring findings up to 24 hours and 4 more. Started Aug 2022; status: completed.
02
Drugs
mangaciclanol
Beyond the preview
Go deeper on NCT05569278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569278.